Back to discover
Disease

Prostate neoplasm

Late-stage therapeutic development
Also known as neoplasm of prostate, neoplasm of prostate gland, neoplasm of the prostate, prostate gland neoplasm+13 more

neoplasm of prostate, neoplasm of prostate gland, neoplasm of the prostate, prostate gland neoplasm, prostate gland neoplasm (disease), prostate gland tumor, prostate gland tumour, prostate tumor, prostate tumour, tumor of prostate, tumor of prostate gland, tumor of the prostate, tumour of prostate, tumour of prostate gland, tumour of the prostate, nodular prostate, prostate nodule.

14
Clinical trials
10
Associated genes
3
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 2 clinical trials expected to report results, the earliest in Q3 2028.
Upcoming Milestones
Clinical Milestones5View
Results posted 1
Results expected 2
Recently completed 1
Other updates 1
Activity timeline5

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Talazoparibapproved

Approval — Treatment with Talzenna should be initiated and supervised by a physician experienced in… (2019)

Clinical trials

11 sponsors · 1 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
14
All trials
3
Active
1
Late-stage
6
Completed
Late-stage studies

Role of Soy Isoflavones in Prostate Cancer Prevention

Phase 3 · Completed · VA Office of Research and Development
Recently completed

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair

Phase 1/2 · Completed · Memorial Sloan Kettering Cancer Center

A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Phase 1/2 · Completed · National Cancer Institute (NCI)

Pilot Study: Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

Phase 1/2 · Completed · Radboud University Medical Center

Measuring the Analgesic Effect of Adding Pre-Operative Single Shot Rectus Sheath Blocks to Post-Operative Rectus Sheath Continuous Blocks for Major Urologic Surgery: A Randomized Controlled Trial

N/A · Completed · University of Alberta

A Pilot Study of F-18 Sodium Fluoride PET/CT for Metastatic Burden Qualification in Prostate Cancer

Phase 2 · Completed · National Cancer Institute (NCI)

Role of Soy Isoflavones in Prostate Cancer Prevention

Phase 3 · Completed · VA Office of Research and Development

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2019emaApproval — Talazoparib· Treatment with Talzenna should be initiated and supervised by a physician experienced in the use of anticancer medicinal products. Patient selection Breast cancer: Patients should be selected for the treatment of breast cancer with Talzenna based on the presence of deleterious or suspected deleterious germline BRCA mutations determined by an experienced laboratory using a validated test method. Genetic counselling for patients with BRCA mutations should be performed according to local regulations, as applicable. Prostate cancer: There is no requirement for tumour mutation testing for selection of patients with mCRPC for treatment with Talzenna. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

10 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CYP17A10.50SRD5A20.39SRD5A10.37SAMD140.04CEACAM200.01MRPS18B0.01NSFL1C0.01AKR1C80.00FAM229A0.00LRRC580.00

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Steroid 17-alpha-hydroxylase/17,20 lyasevia CYP17A10.503-oxo-5-alpha-steroid 4-dehydrogenase 2via SRD5A20.393-oxo-5-alpha-steroid 4-dehydrogenase 1via SRD5A10.37

Reference

Authoritative identity, definition & identifiers.

Synonyms

neoplasm of prostate, neoplasm of prostate gland, neoplasm of the prostate, prostate gland neoplasm, prostate gland neoplasm (disease), prostate gland tumor, prostate gland tumour, prostate tumor, prostate tumour, tumor of prostate, tumor of prostate gland, tumor of the prostate, tumour of prostate, tumour of prostate gland, tumour of the prostate, nodular prostate, prostate nodule

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.